Cardiovascular Risk Profile in Kidney Transplant Recipients Treated With Two Immunosuppressive Regimens: Tacrolimus and Mycophenolate Mofetil Versus Everolimus and Low-Dose Cyclosporine

Franco Citterio, Gionata Spagnoletti, Evaldo Favi, Elisabetta Rossi, Maria Paola Salerno

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)

Abstract

Objective: The aim of this prospective study was to compare the cardiovascular risk (CVR) profile in patients treated with 2 different immunosuppressive regimens: tacrolimus and mycophenolate mofetil (TAC) compared with everolimus and low-dose cyclosporine (EVL). Patients and Methods: Sixty consecutive renal transplant recipients prospectively assigned to TAC (n = 30) or to EVL (n = 30) were followed for 6 months. TAC group immunosuppression consisted of basiliximab, tacrolimus, mycophenolate mofetil (MMF), and steroid. EVL group immunosuppression consisted of basiliximab, everolimus, and low doses of cyclosporine and steroid. Main CVR factors analyzed were: hypertension, dyslipidemia, posttransplant diabetes mellitus, and weight gain. Results: Six months posttransplantation, patients in the EVL group showed significantly higher mean serum cholesterol (P < .003) and serum triglyceride levels (P < .027), as well as a greater number of patients were receiving statin treatment (P < .05). Mean systolic blood pressure, mean diastolic blood pressure, number of patients treated for hypertension, number of antihypertensive medications prescribed per patient, posttransplant weight gain, and posttransplant diabetes mellitus were not significantly different among the EVL and TAC groups after 1, 3, and 6 months posttransplantation. Conclusions: This study showed that at 6 months posttransplantation, patients on EVL displayed significantly greater dyslipidemia with respect to the TAC group. A longer follow-up will be necessary to discover whether the presence of everolimus in the immunosuppressive regimen provides significant benefits for the CVR of renal transplant recipients. © 2009.
Lingua originaleEnglish
pagine (da-a)1175-1177
Numero di pagine3
RivistaTransplantation Proceedings
Volume41
DOI
Stato di pubblicazionePubblicato - 2009

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Basiliximab
  • Cardiovascular Diseases
  • Cyclosporine
  • Drug Therapy, Combination
  • Everolimus
  • Female
  • Graft Rejection
  • Humans
  • Immunosuppressive Agents
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Mycophenolic Acid
  • Prospective Studies
  • Recombinant Fusion Proteins
  • Risk Adjustment
  • Risk Factors
  • Sirolimus
  • Tacrolimus
  • Transplant Recipients

Fingerprint Entra nei temi di ricerca di 'Cardiovascular Risk Profile in Kidney Transplant Recipients Treated With Two Immunosuppressive Regimens: Tacrolimus and Mycophenolate Mofetil Versus Everolimus and Low-Dose Cyclosporine'. Insieme formano una fingerprint unica.

Cita questo